Document is current
Any future updates will be listed below
-
Authors
Cheloni, Giulia
Karagkouni, Dimitra
Pita-Juarez, Yered
Torres, Daniela
Kanata, Eleni https://orcid.org/0009-0009-2828-2226
Liegel, Jessica
Avigan, Zachary
Saldarriaga, Isabella
Chedid, Georges
Rallis, Kathrine
Miles, Brodie
Tiwari, Gayatri
Kim, Jenny
Mattie, Mike
Rosenblatt, Jacalyn
Vlachos, Ioannis S. https://orcid.org/0000-0002-8849-808X
Avigan, David https://orcid.org/0000-0003-4624-6017
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 2 May 2025
First Online: 23 May 2025
Competing interests
: B.Miles, G. Tiwari, J. Kim, and M. Mattie report employment with Kite, a Gilead company, and stock or other ownership in Gilead Sciences. J. Rosenblatt reports consulting with Attivare, Parexel, Clario/Bioclinica, Imaging Endpoint, and Wolters Kluwer Health, Inc. Serves on a DSMB with Karyopharm. Grants and nonfinancial support from Celgene, BMS, and Sanofi outside the submitted work. I.S. Vlachos consults for Guidepoint Global, Chronicle Medical Software Inc., and Mosaic outside of the submitted work. D. Avigan reports grants from MMRF, CTN (NIHLBI), Celgene, Pharmacyclics, AbbVie, and Kite Pharma. Other support from Juno, Partners TX, Karyopharm, BMS, Takeda, Legend Bio Tech, Chugai, Janssen, Parexel, Sanofi, Regeneron, and Arcellix outside the submitted work. D. Avigan and J. Rosenblatt hold a patent, US patent 11, 026,921 entitled, “Compositions and Methods of Treating Cancer”. No disclosures were reported by the other authors. This research was funded by Kite, a Gilead company, Santa Monica, CA, USA.
